Yuhan eyes next Leclaza with R&D, open innovation after U.S.
Aug 23, 2024 — Following the U.S. approval of lung treatment Leclaza, Korea’s first cancer drug to achieve the milestone, Yuhan Corporation is now seeking the next breakthrough with a renewed focus on research and development (R&D).
Gilead gives up on $15M MASH bet after mulling preclinical data
Oct 11, 2024 — The U.S. drugmaker has “mutually agreed” to terminate its collaboration and license agreement with South Korean biotech Yuhan for a pair of MASH therapies.
News – Yuhan USA
Aug 20, 2024 — News – Yuhan USA. RYBREVANT® plus LAZCLUZE™ by Johnson & Johnson got approved by the U.S. FDA as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. LAZCLUZE™ is anti-cancer drug developed by Yuhan Corporation licensed out to Janssen Biotech in 2018.
[Herald Interview] Yuhan aims for bigger presence in US
Jan 11, 2023 — SAN FRANCISCO – South Korean pharmaceutical giant Yuhan is seeking to increase cooperation with researchers and biotechnology firms based in the US, with hopes to benefit from the nation’s...
Yuhan - Wikipedia
Yuhan Corporation (Korean: 주식회사 유한양행; Hanja: 株式會社 柳韓洋行; RR: Jusik Hoesa Yuhan Yanghaeng) is a South Korean pharmaceutical and chemical company headquartered in Daebang-dong, Dongjak-gu, Seoul. It was established in 1926 by New Il-han and has been listed on the Korea Stock Exchange since 1962.
[INTERVIEW] Yuhan USA is searching for its next promising …
Jan 11, 2023 — Yuhan, a Seoul-based biopharmaceutical company best known for its licensing of a novel lung cancer treatment called lazertinib, sold under brand Leclaza, has clinched a deal with Yansen to export the drug and is now looking for its next target.
Yuhan makes $325M cancer bet to challenge Boehringer, Takeda
May 31, 2023 — Yuhan Corporation has bought its way into a cancer space targeted by Boehringer Ingelheim and Takeda, wagering up to $325 million to get its hands on a preclinical HER2 tyrosine kinase inhibitor...
Gilead taps Korea's Yuhan to supply HIV drug ingredients in $81M …
Sep 20, 2024 — In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s Yuhan to help produce its HIV meds in a deal worth $80.9 million.
Biden administration suspends funding for Wuhan lab
Jul 18, 2023 — CNN — The Biden administration has suspended funding for the Wuhan Institute of Virology following a monthslong review that determined that the Chinese research institute “is not compliant with...
Wuhan - BBC News
May 22, 2024 — Animals at the Wuhan Market. What does animal DNA from the Wuhan Market reveal about the start of the pandemic? BBC World Service. Available for over a year. 77 mins. Science In Action. Animals...